Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Caterpillar™ Arterial Embolization Device Post-Market Study (MONARCH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04244370
Recruitment Status : Active, not recruiting
First Posted : January 28, 2020
Last Update Posted : April 8, 2022
Sponsor:
Information provided by (Responsible Party):
C. R. Bard

Brief Summary:
The primary objective of this study is to evaluate the performance and safety of the Caterpillar™ Arterial Embolization Device when used for arterial embolization in the peripheral vasculature in a real world, on-label application.

Condition or disease Intervention/treatment Phase
Embolization, Therapeutic Device: Caterpillar™ Arterial Embolization Device Not Applicable

Detailed Description:
The post-market study is a prospective, multi-center, single-arm, real world study of the Caterpillar™ Arterial Embolization Device. Enrollment will continue until up to fifty (50) subjects have been treated with the Caterpillar™ Arterial Embolization Device at up to 20 investigational sites in the United States.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multi-Center, Single-Arm, Real World Study Assessing the Clinical Use of the Caterpillar™ Arterial Embolization Device for Arterial Embolization in the Peripheral Vasculature (MONARCH)
Actual Study Start Date : April 30, 2020
Actual Primary Completion Date : August 13, 2021
Estimated Study Completion Date : July 2022

Arm Intervention/treatment
Experimental: Caterpillar™ Arterial Embolization Device
Placement of the Caterpillar™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
Device: Caterpillar™ Arterial Embolization Device
Placement of the Caterpillar™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
Other Names:
  • Caterpillar™ Micro (027)
  • Caterpillar™ (038 & 056)




Primary Outcome Measures :
  1. Technical Success [ Time Frame: Index Procedure ]
    Successful occlusion of the target embolization site(s) as confirmed by the Investigator via angiographic assessment during the Index Procedure. Technical success will be reported for each target embolization site.

  2. Freedom from Device-Related SAEs [ Time Frame: 30 (-7/+21) Days ]
    Freedom from device-related serious adverse events (SAE) through 30-day follow-up.


Secondary Outcome Measures :
  1. Time Point of Occlusion [ Time Frame: Index Procedure ]
    The percentage of target embolization site(s) with occlusion at ≤1, ≤2, ≤3, ≤4, ≤5, ≤10 and >10 minutes post-treatment.

  2. Freedom from Recanalization [ Time Frame: 30 (-7/+21) days, 6 months (±30 days) and 12 months (±30 days) ]
    Freedom from clinically relevant recanalization of the target embolization site(s) through 30-days, 6 and 12-months follow-up as confirmed by the Investigator. Clinically relevant recanalization is defined as recanalization through the study device that requires a re-intervention. Freedom from recanalization will be reported for each target embolization site.

  3. Freedom from Migration [ Time Frame: 30 (-7/+21) days, 6 months (±30 days) and 12 months (±30 days) ]

    Freedom from Migration will be reported for each study device as follows:

    • Freedom from clinically relevant acute migration of the study device(s) as confirmed by the Investigator via angiographic assessment during the Index Procedure. Clinically relevant migration is defined as migration of the study device from the target embolization site that requires intervention.
    • Freedom from clinically relevant migration of the study device(s) through 30-days, 6 and 12-months follow-up as confirmed by the Investigator. Clinically relevant migration is defined as migration of the study device from the target embolization site that requires a re-intervention.

  4. Freedom from Device and/or Procedure-Related Adverse Events [ Time Frame: 30 (-7/+21) days, 6 months (±30 days) and 12 months (±30 days) ]
    Freedom from device and/or procedure-related adverse events (AE) through 30-days, 6 and 12-months follow-up.

  5. Accuracy of Delivery [ Time Frame: Index Procedure ]
    Accurate delivery of the study device to the target embolization site as assessed by the Investigator.

  6. Ease of Trackability/Deliverability [ Time Frame: Index Procedure ]
    Ease of study device trackability and deliverability as assessed by the Investigator.

  7. Ease of Detachment [ Time Frame: Index Procedure ]
    Ease of study device detachment as assessed by the Investigator.

  8. Acceptability of Visibility [ Time Frame: Index Procedure ]
    Acceptability of study device visibility under fluoroscopy as assessed by the Investigator.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject or Legally Authorized Representative (LAR) must voluntarily sign and date the approved Informed Consent Form (ICF) prior to collection of study-specific data or performance of study-specific procedures.
  2. Subject must be either male or non-pregnant female ≥18 years of age with an expected lifespan sufficient to allow for completion of all study procedures.
  3. Subject must be willing and able to comply with protocol requirements, including all study visits and procedures.
  4. Subject must require peripheral vascular occlusion at an arterial target embolization site(s) that can be treated with the Caterpillar™ Arterial Embolization Device according to the Instructions for Use (IFU). Note: Per Investigator discretion, up to five (5) Target Embolization Sites may be treated with up to ten (10) study devices per subject.

    Angiographic Inclusion Criteria

  5. The target embolization site(s) must be located in a native arterial vessel(s) with the intended arterial vessel diameter ranges shown in the IFU, as assessed by the Investigator (via visual estimate).
  6. The target embolization site(s) must have a landing zone sufficient to accommodate the device implant lengths shown in the IFU.

Exclusion Criteria:

  1. The subject's access vessel(s) preclude safe insertion of the delivery catheter.
  2. The subject's target embolization site(s) is located within a vein.
  3. The subject's target embolization site(s) is located within the head, neck, heart or coronary vessels.
  4. The subject's target embolization site(s) is located across highly locomotive joints or muscle beds (e.g. elbow, hip, knee, shoulder, thoracic inlet/outlet).
  5. The subject's target embolization site(s) is located in a high-flow vessel where, in the opinion of the Investigator, there may be significant risk of migration and unintended (non-target site) occlusion.
  6. The subject has a known allergy or hypersensitivity to contrast media that cannot be adequately pre-medicated.
  7. The subject has a known allergy or hypersensitivity to any of the device materials including: cobalt, chromium, nickel, titanium, platinum, iridium, polyurethane or polyethylene.
  8. The subject has planned use of anticoagulant (e.g. direct thrombin inhibitors, factor Xa inhibitors, vitamin K antagonists) or antiplatelet therapy before, during and/or after treatment with the study device, which, in the opinion of the Investigator, would clinically interfere with the study endpoints.
  9. The subject has a known uncontrolled blood coagulation or bleeding disorder.
  10. The subject has an unresolved systemic infection.
  11. The subject's required pre-operative laboratory tests and/or physical examination indicate abnormal results, which, in the opinion of the Investigator, would clinically interfere with the study endpoints.
  12. The subject has a connective tissue disorders (e.g. Ehlers-Danlos Syndrome), arteritis (e.g. Takayasu's Disease) or another circulatory disorder, which, in the opinion of the Investigator, would clinically interfere with the study endpoints.
  13. The subject has another medical condition which, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, may confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.
  14. The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04244370


Locations
Layout table for location information
United States, Arizona
Dignity Health/St. Joseph's & Medical Center
Phoenix, Arizona, United States, 85013
United States, Florida
Baptist Hospital of Miami
Miami, Florida, United States, 33176
United States, Indiana
Indiana University School of Medicine
Indianapolis, Indiana, United States, 46202
United States, Kansas
University of Kansas Medical Center Research Institute
Kansas City, Kansas, United States, 66160
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
United States, Minnesota
University of Minnesota Medical Center - Fairview
Minneapolis, Minnesota, United States, 55455
United States, Pennsylvania
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
United States, Texas
Cardiothoracic and Vascular Surgeons
Austin, Texas, United States, 78756
University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030
United States, Wisconsin
The Medical College of Wisconsin, Inc.
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
C. R. Bard
Investigators
Layout table for investigator information
Principal Investigator: William Rilling, MD, FSIR Medical College of Wisconsin
Layout table for additonal information
Responsible Party: C. R. Bard
ClinicalTrials.gov Identifier: NCT04244370    
Other Study ID Numbers: BPV-18-001
First Posted: January 28, 2020    Key Record Dates
Last Update Posted: April 8, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by C. R. Bard:
Arterial Embolization
Vascular Plug